We’ve prepared a selected collection of our best-selling screening libraries in pre-plated format. Take advantage of most favorable terms to boost your hit-finding HTS drug discovery projects! The compound sets comprise novel drug-like screening compounds synthesized in-house. Several formatting options are available.

An early assessment of solubility provides valuable information for better interpretation of screening results and the design of new molecules in drug discovery projects. Explore our 20,000 readily available fragments with confirmed solubility in PBS and DMSO! The Library is regularly updated with newly synthesized compounds, rigorously filtered by physicochemical and structural parameters.

Find your promising drug candidates among our 2.5 million Tangible Screening Compounds! We have designed this unique collection applying the most advanced cheminformatics approaches and drug-like scaffolds. These original feasible molecules can be synthesized to customers’ orders by means of our in-house validated chemical procedures.

Life Chemicals has developed two screening compound subsets using 2D fingerprint similarity search (3,500 compounds) and docking-based virtual screening (8,000 compounds) to boost epigenetic-related drug discovery efforts. The selected structurally-diverse molecules are predicted to modulate a number of most promising epigenetic targets.

Over 3,300 structurally-diverse molecules for biological screening have been selected, using structure-based and ligand-based approaches. The proprietary in silico screening platform was employed to predict new types of active compounds with potential inhibitory activity against E1 activating protein and ubiquitin-specific proteases USP1, 2.

PDE10 is an attractive drug target in search of effective and selective treatment of psychiatric and neurological disorders. To facilitate CNS-related drug discovery, we have chosen 1,450 structurally-diverse screening compounds with PDE10 inhibitory activity, employing a combined virtual screening approach that employed 3D pharmacophore modelling and molecular docking.

We offer over 1,400 small-molecule analogs of known aspartic proteinase inhibitors, selected with a 2D fingerprint similarity. Moreover, our docking-based virtual screening has provided over 2,300 drug-like screening compounds with potential renin-binding activity. Being part of RAAS, the renin inhibition may give a new insight into anti-coronavirus and hypertension drug discovery.

ATPases are crucial enzymes engaged in energy homeostasis and signal transduction. Mutations in these proteins account for various diseases from cancer to osteoporosis, immune deficiency disease, nephrotoxicity, cystic fibrosis, and diabetes. We have selected over 8,800 drug-like screening compounds with potential ATPase inhibitory activity for drug discovery HTS projects. A pre-plated set based on this Screening Library is also available.